sb 203580 has been researched along with carboplatin in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (carboplatin) | Trials (carboplatin) | Recent Studies (post-2010) (carboplatin) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 12,895 | 4,001 | 5,244 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, H; Fu, Y; Han, X; Postovit, LM; Steed, H; Zhou, J | 1 |
1 other study(ies) available for sb 203580 and carboplatin
Article | Year |
---|---|
Pharmacological Inhibition of p38 MAPK by SB203580 Increases Resistance to Carboplatin in A2780cp Cells and Promotes Growth in Primary Ovarian Cancer Cells.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Imidazoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Tumor Cells, Cultured | 2018 |